002422 科伦药业
已收盘 07-28 15:00:00
资讯
新帖
简况
科伦药业获得外观设计专利授权：“药品包装盒（盐酸伐地那非片）”
证券之星 · 07-24
科伦药业获得外观设计专利授权：“药品包装盒（盐酸伐地那非片）”
沪深300制药指数报12172.19点，前十大权重包含科伦药业等
金融界 · 07-24
沪深300制药指数报12172.19点，前十大权重包含科伦药业等
科伦药业：保障业务可持续发展平衡股东利益
证券之星 · 07-22
科伦药业：保障业务可持续发展平衡股东利益
科伦药业：关于董事辞职的公告
新浪财经-鹰眼工作室 · 07-09
科伦药业：关于董事辞职的公告
科伦药业股价下跌3.13% 国家药监局注销56个药品注册证书
金融界 · 07-08
科伦药业股价下跌3.13% 国家药监局注销56个药品注册证书
科伦药业获得外观设计专利授权：“包装盒（康复新液）”
证券之星 · 06-30
科伦药业获得外观设计专利授权：“包装盒（康复新液）”
中证制药指数上涨0.9%，前十大权重包含科伦药业等
金融界 · 06-24
中证制药指数上涨0.9%，前十大权重包含科伦药业等
科伦药业收盘上涨1.79%，滚动市盈率22.17倍，总市值552.93亿元
金融界 · 06-23
科伦药业收盘上涨1.79%，滚动市盈率22.17倍，总市值552.93亿元
交银国际：将科伦药业评级下调至中性，目标价40.20元。
金融界 · 06-19
交银国际：将科伦药业评级下调至中性，目标价40.20元。
科伦药业新动作！1175万收购新三板药企孙公司100%股权
红星资本局 · 06-17
科伦药业新动作！1175万收购新三板药企孙公司100%股权
科伦药业：公司控股子公司科伦博泰已建立具备ADC、大分子（mAb及bsAb）及小分子药物专有技术的内部开发技术平台
证券之星 · 06-16
科伦药业：公司控股子公司科伦博泰已建立具备ADC、大分子（mAb及bsAb）及小分子药物专有技术的内部开发技术平台
中证创新药30指数下跌2.21%，前十大权重包含科伦药业等
金融界 · 06-13
中证创新药30指数下跌2.21%，前十大权重包含科伦药业等
每周股票复盘：科伦药业（002422）科伦博泰配售5,918,000股H股，净筹19.43亿港元
证券之星 · 06-06
每周股票复盘：科伦药业（002422）科伦博泰配售5,918,000股H股，净筹19.43亿港元
科伦药业(002422.SZ)：科伦博泰拟配售591.8万股H股股份
智通财经 · 06-05
科伦药业(002422.SZ)：科伦博泰拟配售591.8万股H股股份
翻倍大妖股，突然跌停！
格隆汇 · 05-30
翻倍大妖股，突然跌停！
科伦药业最新公告：子公司根据SKB378/HBM9378/WIN378的独占性许可协议收到现金及股权支付的首付款
证券之星 · 05-23
科伦药业最新公告：子公司根据SKB378/HBM9378/WIN378的独占性许可协议收到现金及股权支付的首付款
科伦药业：科伦博泰生物研发项目有海外授权详细内容见公司2024年年报
证券之星 · 05-23
科伦药业：科伦博泰生物研发项目有海外授权详细内容见公司2024年年报
科伦药业：这两笔质押实际购回日为2025年5月22日
证券之星 · 05-23
科伦药业：这两笔质押实际购回日为2025年5月22日
A股创新药概念股持续走高：阳光诺和冲击20CM涨停，信立泰、科伦药业均创历史新高
格隆汇 · 05-23
A股创新药概念股持续走高：阳光诺和冲击20CM涨停，信立泰、科伦药业均创历史新高
【创新药概念股持续走高 信立泰、科伦药业双双创历史新高】信立泰、科伦药业双双创历史新高，阳光诺和冲击20CM涨停，众生药业此前涨停，海辰药业、贝达药业、泓博医药涨超10%，舒泰神、海翔药业、泰格医药、华海药业等多股涨超5%。
金融界 · 05-23
【创新药概念股持续走高 信立泰、科伦药业双双创历史新高】信立泰、科伦药业双双创历史新高，阳光诺和冲击20CM涨停，众生药业此前涨停，海辰药业、贝达药业、泓博医药涨超10%，舒泰神、海翔药业、泰格医药、华海药业等多股涨超5%。
加载更多
公司概况
公司名称：
四川科伦药业股份有限公司
所属行业：
医药制造业
上市日期：
2010-06-03
主营业务：
四川科伦药业股份有限公司的主营业务是大容量注射剂（输液）、小容量注射剂（水针）、注射用无菌粉针（含分装粉针及冻干粉针）、片剂、胶囊剂、颗粒剂、口服液、腹膜透析液等24种剂型药品及抗生素中间体、原料药、医药包材等产品的研发、生产和销售。公司的主要产品是输液、非输液、研发项目、其他。
发行价格：
83.36
{"stockData":{"symbol":"002422","market":"SZ","secType":"STK","nameCN":"科伦药业","latestPrice":35.21,"timestamp":1753686225000,"preClose":35.17,"halted":0,"volume":14578676,"delay":0,"changeRate":0.0011,"floatShares":1306000000,"shares":1598000000,"eps":1.5607,"marketStatus":"已收盘","change":0.04,"latestTime":"07-28 15:00:00","open":35.29,"high":35.9,"low":34.9,"amount":514000000,"amplitude":0.0284,"askPrice":35.22,"askSize":93,"bidPrice":35.21,"bidSize":52,"shortable":0,"etf":0,"ttmEps":1.5607,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753752600000},"marketStatusCode":5,"adr":0,"adjPreClose":35.17,"symbolType":"stock","openAndCloseTimeList":[[1753666200000,1753673400000],[1753678800000,1753686000000]],"highLimit":38.69,"lowLimit":31.65,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1598053372,"isCdr":false,"pbRate":2.43,"roa":"--","peRate":22.56039,"roe":"2.56%","epsLYR":1.86,"committee":-0.024705,"marketValue":56267000000,"turnoverRate":0.0112,"status":0,"floatMarketCap":45980000000},"requestUrl":"/m/hq/s/002422","defaultTab":"news","newsList":[{"id":"2554993787","title":"科伦药业获得外观设计专利授权：“药品包装盒（盐酸伐地那非片）”","url":"https://stock-news.laohu8.com/highlight/detail?id=2554993787","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554993787?lang=zh_cn&edition=full","pubTime":"2025-07-25 02:26","pubTimestamp":1753381591,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示科伦药业新获得一项外观设计专利授权，专利名为“药品包装盒”，专利申请号为CN202430698335.X，授权日为2025年7月25日。今年以来科伦药业新获得专利授权27个，较去年同期增加了17.39%。通过天眼查大数据分析，四川科伦药业股份有限公司共对外投资了46家企业，参与招投标项目8415次；财产线索方面有商标信息1120条，专利信息2032条，著作权信息12条；此外企业还拥有行政许可1049个。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072500002374.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","BK0239","LU2148510915.USD","LU1934453819.USD","LU1064130708.USD","BK0060","002422","LU1979443071.USD"],"gpt_icon":0},{"id":"2553277306","title":"沪深300制药指数报12172.19点，前十大权重包含科伦药业等","url":"https://stock-news.laohu8.com/highlight/detail?id=2553277306","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553277306?lang=zh_cn&edition=full","pubTime":"2025-07-24 15:17","pubTimestamp":1753341442,"startTime":"0","endTime":"0","summary":"金融界7月24日消息，上证指数低开高走，沪深300制药指数 报12172.19点。数据统计显示，沪深300制药指数近一个月上涨6.10%，近三个月上涨5.82%，年至今上涨11.74%。据了解，沪深300制药指数从沪深300指数中选取与制药主题相对应的行业内上市公司证券作为指数样本，以反映该主题上市公司证券的整体表现。该指数以2004年12月31日为基日，以1000.0点为基点。从沪深300制药指数持仓样本的行业来看，药品制剂占比64.85%、中成药占比29.47%、原料药占比5.68%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724152336971b7d1d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724152336971b7d1d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600085","LU1979443071.USD","002422","BK0060","000001.SH","BK0096","600196","BK0239","BK0187","BK0188","159919","688506","LU1064131003.USD","399300","600436","LU2148510915.USD","BK0012","02196","BK0196","LU1934453819.USD","BK0183","BK0028","LU1064130708.USD","BK0175"],"gpt_icon":0},{"id":"2553840033","title":"科伦药业：保障业务可持续发展平衡股东利益","url":"https://stock-news.laohu8.com/highlight/detail?id=2553840033","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553840033?lang=zh_cn&edition=full","pubTime":"2025-07-22 09:01","pubTimestamp":1753146085,"startTime":"0","endTime":"0","summary":"查询公司过往年度的股利支付率大多都在50%，甚至60%以上。但2024年度的股利支付率却降为41%。为保障公司业务可持续发展、平衡股东短期和长期利益，制定该分红预案，感谢您对公司的关注。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072200007494.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","002422","LU1064130708.USD","LU1064131003.USD","LU1934453819.USD","LU1979443071.USD","LU2148510915.USD"],"gpt_icon":0},{"id":"2550884636","title":"科伦药业：关于董事辞职的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2550884636","media":"新浪财经-鹰眼工作室","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550884636?lang=zh_cn&edition=full","pubTime":"2025-07-09 18:00","pubTimestamp":1752055200,"startTime":"0","endTime":"0","summary":"四川科伦药业股份有限公司关于董事辞职的公告本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗漏。王广基先生系任期届满前辞职，其辞职报告自送达公司董事会之日起生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2025-07-09/doc-infewkcp2719526.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1064130708.USD","LU2148510915.USD","LU1934453819.USD","LU1064131003.USD","LU1979443071.USD","BK0060","BK0239","002422"],"gpt_icon":0},{"id":"2550079522","title":"科伦药业股价下跌3.13% 国家药监局注销56个药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2550079522","media":"金融界","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550079522?lang=zh_cn&edition=full","pubTime":"2025-07-09 01:46","pubTimestamp":1751996814,"startTime":"0","endTime":"0","summary":"科伦药业股价报33.40元，较前一交易日下跌1.08元，跌幅3.13%。盘中最高触及34.69元，最低下探至33.15元，成交金额达10.22亿元。科伦药业主要从事大容量注射剂、小容量注射剂、片剂、胶囊剂等药品的研发、生产和销售。国家药监局近日发布公告注销56个药品注册证书，其中包括科伦药业旗下产品。公告显示这些药品均为企业主动申请注销，涉及多种情况包括被重点监控、限制使用等。在注销名单中，外企产品占比过半，与集采、医保等政策因素密切相关。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/09014651571429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU1064130708.USD","BK0060","002422","BK0239","LU1979443071.USD","LU2148510915.USD","LU1934453819.USD","LU1064131003.USD"],"gpt_icon":0},{"id":"2548012526","title":"科伦药业获得外观设计专利授权：“包装盒（康复新液）”","url":"https://stock-news.laohu8.com/highlight/detail?id=2548012526","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548012526?lang=zh_cn&edition=full","pubTime":"2025-07-01 02:46","pubTimestamp":1751309208,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示科伦药业新获得一项外观设计专利授权，专利名为“包装盒”，专利申请号为CN202430698337.9，授权日为2025年7月1日。今年以来科伦药业新获得专利授权25个，较去年同期增加了13.64%。通过天眼查大数据分析，四川科伦药业股份有限公司共对外投资了46家企业，参与招投标项目8355次；财产线索方面有商标信息1120条，专利信息2068条，著作权信息12条；此外企业还拥有行政许可1046个。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070100003003.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","LU1934453819.USD","LU1064130708.USD","LU1979443071.USD","LU1064131003.USD","LU2148510915.USD","BK0239","002422"],"gpt_icon":0},{"id":"2545239939","title":"中证制药指数上涨0.9%，前十大权重包含科伦药业等","url":"https://stock-news.laohu8.com/highlight/detail?id=2545239939","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545239939?lang=zh_cn&edition=full","pubTime":"2025-06-24 23:08","pubTimestamp":1750777733,"startTime":"0","endTime":"0","summary":"金融界6月24日消息，上证指数低开高走，中证制药指数 上涨0.9%，报2112.11点，成交额179.14亿元。数据统计显示，中证制药指数近一个月下跌0.95%，近三个月上涨7.33%，年至今上涨6.60%。据了解，中证制药指数选取业务涉及中药、化学药和生物药的上市公司证券作为指数样本，以反映制药主题上市公司证券的整体表现。该指数以2011年12月30日为基日，以1000.0点为基点。从中证制药指数持仓样本的行业来看，医药卫生占比100.00%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/24230851284046.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","002422","BK1574","LU1979443071.USD","BK0060","LU2148510915.USD","01477","LU1064130708.USD","LU1934453819.USD","LU1064131003.USD","BK0239"],"gpt_icon":0},{"id":"2545499391","title":"科伦药业收盘上涨1.79%，滚动市盈率22.17倍，总市值552.93亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2545499391","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545499391?lang=zh_cn&edition=full","pubTime":"2025-06-23 16:41","pubTimestamp":1750668101,"startTime":"0","endTime":"0","summary":"6月23日，科伦药业今日收盘34.6元，上涨1.79%，滚动市盈率PE达到22.17倍，总市值552.93亿元。从行业市盈率排名来看，公司所处的化学制药行业市盈率平均53.59倍，行业中值30.86倍，科伦药业排名第65位。截至2025年一季报，共有143家机构持仓科伦药业，其中基金140家、其他2家、券商1家，合计持股数43250.60万股，持股市值139.40亿元。最新一期业绩显示，2025年一季报，公司实现营业收入43.90亿元，同比-29.42%；净利润5.84亿元，同比-43.07%，销售毛利率48.67%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/23164151240228.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","LU1979443071.USD","002422","LU1064130708.USD","LU2148510915.USD","BK0060","LU1934453819.USD","LU1064131003.USD"],"gpt_icon":0},{"id":"2544539182","title":"交银国际：将科伦药业评级下调至中性，目标价40.20元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2544539182","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544539182?lang=zh_cn&edition=full","pubTime":"2025-06-19 09:07","pubTimestamp":1750295231,"startTime":"0","endTime":"0","summary":"交银国际：将科伦药业评级下调至中性，目标价40.20元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/06/19090751162436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["002422"],"gpt_icon":0},{"id":"2544957887","title":"科伦药业新动作！1175万收购新三板药企孙公司100%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2544957887","media":"红星资本局","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544957887?lang=zh_cn&edition=full","pubTime":"2025-06-17 16:52","pubTimestamp":1750150320,"startTime":"0","endTime":"0","summary":"6月17日，科伦药业回应微成都称，此次收购后将加强公司在江苏市场的产业布局。据公告，科伦药业认可江苏华世通的经营理念和发展潜力，拟以江苏华世通作为药品B证公司的主体进行药品生产和经营为目的，通过收购江苏华世通100%股权的方式进行投资，由此享受来自江苏华世通的投资收益。据微成都此前报道，2024年科伦药业交出了上市以来最佳成绩单，营收同比增长1.67%至218.12亿元，归母净利润同比增长19.53%至29.36亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/cj/2025-06-17/doc-infakprc9791009.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1979443071.USD","BK0060","BK0239","LU1064130708.USD","LU1934453819.USD","LU1064131003.USD","002422","LU2148510915.USD"],"gpt_icon":0},{"id":"2543617137","title":"科伦药业：公司控股子公司科伦博泰已建立具备ADC、大分子（mAb及bsAb）及小分子药物专有技术的内部开发技术平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2543617137","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543617137?lang=zh_cn&edition=full","pubTime":"2025-06-16 08:42","pubTimestamp":1750034533,"startTime":"0","endTime":"0","summary":"证券之星消息，科伦药业(002422)06月16日在投资者关系平台上答复投资者关心的问题。投资者提问：请问：公司在双抗药物研发方面有吗？进展如何？科伦药业回复：尊敬的投资者您好，公司控股子公司科伦博泰已建立具备ADC、大分子（mAb及bsAb）及小分子药物专有技术的内部开发技术平台，以支援其药物的研发。其成熟的大分子平台可用于创建及完善前沿mAb/bsAb疗法，贯穿整个药物开发生命周期。产品进展敬请关注公司后续公告，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061600000631.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002422","BK0060","BK0239","LU2148510915.USD","LU1934453819.USD","LU1064131003.USD","LU1979443071.USD","LU1064130708.USD"],"gpt_icon":0},{"id":"2543684675","title":"中证创新药30指数下跌2.21%，前十大权重包含科伦药业等","url":"https://stock-news.laohu8.com/highlight/detail?id=2543684675","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543684675?lang=zh_cn&edition=full","pubTime":"2025-06-13 20:09","pubTimestamp":1749816558,"startTime":"0","endTime":"0","summary":"金融界6月13日消息，上证指数低开低走，中证创新药30指数 下跌2.21%，报2679.58点，成交额222.46亿元。数据统计显示，中证创新药30指数近一个月上涨17.81%，近三个月上涨22.96%，年至今上涨28.21%。据了解，中证创新药30指数从沪深市场属于创新药行业的上市公司中，选取30只研发投入较高且具备成长特征的上市公司证券作为指数样本，以反映沪深市场较具成长潜力的创新药上市公司证券的整体表现。从中证创新药30指数持仓样本的行业来看，医药卫生占比100.00%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/13200951063794.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","BK0060","BK1574","LU1934453819.USD","BK0239","002422","LU1064130708.USD","LU1064131003.USD","LU2148510915.USD","159992","06978","LU1979443071.USD"],"gpt_icon":0},{"id":"2541985298","title":"每周股票复盘：科伦药业（002422）科伦博泰配售5,918,000股H股，净筹19.43亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2541985298","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541985298?lang=zh_cn&edition=full","pubTime":"2025-06-07 03:54","pubTimestamp":1749239653,"startTime":"0","endTime":"0","summary":"截至2025年6月6日收盘，科伦药业报收于37.47元，较上周的38.56元下跌2.83%。本周，科伦药业6月4日盘中最高价报40.73元。配售后，科伦博泰的股份总数将变更为233,185,969股，科伦药业及其全资子公司科伦国际发展有限公司合计直接持有科伦博泰约53.41%股份，科伦药业仍为科伦博泰的控股股东。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060700007092.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","002422","LU1979443071.USD","LU2148510915.USD","LU1064130708.USD","BK0239","LU1934453819.USD","LU1064131003.USD"],"gpt_icon":0},{"id":"2541012729","title":"科伦药业(002422.SZ)：科伦博泰拟配售591.8万股H股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2541012729","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541012729?lang=zh_cn&edition=full","pubTime":"2025-06-05 11:57","pubTimestamp":1749095833,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦药业(002422.SZ)发布公告，公司近日获悉公司控股子公司四川科伦博泰生物医药股份有限公司(“科伦博泰”)根据其股东大会的发行股份的一般性授权，于2025年6月5日与2名配售代理订立配售协议，根据协议约定，配售代理同意促使向不少于6名承配人配售591.8万股科伦博泰H股股份，配售价格为331.8港元/股，本次配售的完成取决于配售协议约定的若干先决条件的达成。本次配售所得款项净额预计为19.43亿港元，将用于科伦博泰的(1)产品的研发、临床试验、注册备案、制造及商业化;(2)提升内部研发技术能力、加强外部合作及拓展产品管线组合;(3)补充营运资金及作一般企业用途。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1301564.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064130708.USD","BK0239","BK0060","002422","LU1064131003.USD","LU1934453819.USD","LU1979443071.USD","LU2148510915.USD"],"gpt_icon":0},{"id":"2539229995","title":"翻倍大妖股，突然跌停！","url":"https://stock-news.laohu8.com/highlight/detail?id=2539229995","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539229995?lang=zh_cn&edition=full","pubTime":"2025-05-30 18:52","pubTimestamp":1748602353,"startTime":"0","endTime":"0","summary":"又一次资本狂欢大戏","market":"hk","thumbnail":"https://img3.gelonghui.com/c93d2-1339a763-b4a0-4df1-a92c-8d96c6d6b490.jpg?guru_height=803&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/c93d2-1339a763-b4a0-4df1-a92c-8d96c6d6b490.jpg?guru_height=803&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/2262105","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK0229","LU1997245094.SGD","LU1064131003.USD","LU2148510915.USD","BK0239","603605","002422","BK0209","LU1820825898.SGD","LU1979443071.USD","LU1064130708.USD","LU2460026573.USD","BK0060","LU0593848301.USD","LU1934453819.USD","LU1997245177.USD","LU1146622755.USD","300740","605136"],"gpt_icon":0},{"id":"2537853181","title":"科伦药业最新公告：子公司根据SKB378/HBM9378/WIN378的独占性许可协议收到现金及股权支付的首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2537853181","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537853181?lang=zh_cn&edition=full","pubTime":"2025-05-23 17:16","pubTimestamp":1747991798,"startTime":"0","endTime":"0","summary":"科伦药业(002422.SZ)公告称，公司控股子公司科伦博泰已根据与Windward Bio关于SKB378/HBM9378/WIN378的独占性许可协议，收到Windward Bio支付的首付款，包括现金付款和股权。现金付款于2025年2月收到，股权交割于2025年5月完成。SKB378/HBM9378/WIN378是一种新型的重组全人源单克隆抗体，用于治疗慢性阻塞性肺疾病和哮喘。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052300026485.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","LU1064130708.USD","LU1979443071.USD","LU1064131003.USD","BK0239","LU2148510915.USD","LU1934453819.USD","002422"],"gpt_icon":0},{"id":"2537900969","title":"科伦药业：科伦博泰生物研发项目有海外授权详细内容见公司2024年年报","url":"https://stock-news.laohu8.com/highlight/detail?id=2537900969","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537900969?lang=zh_cn&edition=full","pubTime":"2025-05-23 15:48","pubTimestamp":1747986494,"startTime":"0","endTime":"0","summary":"证券之星消息，科伦药业(002422)05月23日在投资者关系平台上答复投资者关心的问题。投资者提问：公司有没可以买给海外大药企的在研产品啊科伦药业回复：尊敬的投资者您好，科伦博泰生物研发项目有海外授权，详细内容见公司2024年年报。公司将持续深化与国际大型医药公司合作，感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052300020104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","BK0060","BK0239","LU1064130708.USD","002422","LU1979443071.USD","LU1934453819.USD","LU2148510915.USD"],"gpt_icon":0},{"id":"2537900961","title":"科伦药业：这两笔质押实际购回日为2025年5月22日","url":"https://stock-news.laohu8.com/highlight/detail?id=2537900961","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537900961?lang=zh_cn&edition=full","pubTime":"2025-05-23 15:48","pubTimestamp":1747986492,"startTime":"0","endTime":"0","summary":"证券之星消息，科伦药业(002422)05月23日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，贵公司于2025-05-23披露的解除公告中，有两笔解除日期为2025-06-13，为未来时，是否有误？请问具体的解除时间是哪天呢？科伦药业回复：尊敬的投资者您好，这两笔质押实际购回日为2025年5月22日，公告表中所示解除日为协议上原定的购回交易日，感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052300020097.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1979443071.USD","BK0239","LU1064130708.USD","LU1064131003.USD","LU1934453819.USD","002422","LU2148510915.USD","BK0060"],"gpt_icon":0},{"id":"2537010229","title":"A股创新药概念股持续走高：阳光诺和冲击20CM涨停，信立泰、科伦药业均创历史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2537010229","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537010229?lang=zh_cn&edition=full","pubTime":"2025-05-23 13:43","pubTimestamp":1747979036,"startTime":"0","endTime":"0","summary":"格隆汇5月23日｜A股市场创新药概念股午后进一步走高，其中，信立泰、科伦药业双双创历史新高，阳光诺和冲击20CM涨停，众生药业此前涨停，海辰药业、贝达药业、泓博医药涨超10%，舒泰神、海翔药业、泰格医药、华海药业等多股涨超5%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505231346199762dc35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505231346199762dc35&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0060","BK0187","159982","LU1934453819.USD","002294","399300","LU1979443071.USD","BK0028","688621","LU1064130708.USD","BK0196","LU1064131003.USD","BK0216","BK0188","BK0183","BK0239","002422","LU2148510915.USD","159992"],"gpt_icon":0},{"id":"2537909219","title":"【创新药概念股持续走高 信立泰、科伦药业双双创历史新高】信立泰、科伦药业双双创历史新高，阳光诺和冲击20CM涨停，众生药业此前涨停，海辰药业、贝达药业、泓博医药涨超10%，舒泰神、海翔药业、泰格医药、华海药业等多股涨超5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2537909219","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537909219?lang=zh_cn&edition=full","pubTime":"2025-05-23 13:43","pubTimestamp":1747979032,"startTime":"0","endTime":"0","summary":"信立泰、科伦药业双双创历史新高，阳光诺和冲击20CM涨停，众生药业此前涨停，海辰药业、贝达药业、泓博医药涨超10%，舒泰神、海翔药业、泰格医药、华海药业等多股涨超5%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/23134350613166.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0192","BK1161","300558","002317","300347","LU1934453819.USD","03347","LU1064131003.USD","BK0183","BK0188","BK0012","BK0028","300584","BK0185","LU1820825898.SGD","LU1979443071.USD","BK0201","BK1583","002422","159992","300204","BK1141","002099","BK1574","002294","LU1064130708.USD","BK0046","06978","BK0060","301230","LU1146622755.USD","600521","BK0070","BK0239","BK0174","BK0077","BK0187","BK0196","LU2148510915.USD","BK1576","688621","BK0216"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1753737552206,"stockEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.017},{"period":"3month","weight":0.0834},{"period":"6month","weight":0.2678},{"period":"1year","weight":0.1667},{"period":"ytd","weight":0.1916}],"compareEarnings":[{"period":"1week","weight":0.0107},{"period":"1month","weight":0.0507},{"period":"3month","weight":0.0947},{"period":"6month","weight":0.1069},{"period":"1year","weight":0.2446},{"period":"ytd","weight":0.0734}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"四川科伦药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"33389人(较上一季度减少16.75%)","perCapita":"39110股","listingDate":"2010-06-03","address":"四川省成都市新都区新都卫星城工业开发区南二路","registeredCapital":"159805万元","survey":" 四川科伦药业股份有限公司的主营业务是大容量注射剂（输液）、小容量注射剂（水针）、注射用无菌粉针（含分装粉针及冻干粉针）、片剂、胶囊剂、颗粒剂、口服液、腹膜透析液等24种剂型药品及抗生素中间体、原料药、医药包材等产品的研发、生产和销售。公司的主要产品是输液、非输液、研发项目、其他。","listedPrice":83.36},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科伦药业(002422)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科伦药业(002422)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科伦药业,002422,科伦药业股票,科伦药业股票老虎,科伦药业股票老虎国际,科伦药业行情,科伦药业股票行情,科伦药业股价,科伦药业股市,科伦药业股票价格,科伦药业股票交易,科伦药业股票购买,科伦药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科伦药业(002422)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科伦药业(002422)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}